Warning! GuruFocus detected
2 Severe warning signs
with UBX.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Unity Biotechnology Inc
NAICS : 325411
SIC : 2833
ISIN : US91381U1016
Description
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.99 | |||||
| Equity-to-Asset | 0.17 | |||||
| Debt-to-Equity | 3.63 | |||||
| Debt-to-EBITDA | -0.94 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 46.6 | |||||
| 3-Year EPS without NRI Growth Rate | 47.2 | |||||
| 3-Year FCF Growth Rate | 46.5 | |||||
| 3-Year Book Growth Rate | -65.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 29.69 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 19.92 | |||||
| 9-Day RSI | 23.27 | |||||
| 14-Day RSI | 27.94 | |||||
| 3-1 Month Momentum % | 32.03 | |||||
| 6-1 Month Momentum % | 15.75 | |||||
| 12-1 Month Momentum % | 7.64 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.62 | |||||
| Quick Ratio | 2.62 | |||||
| Cash Ratio | 2.51 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -38.9 | |||||
| Shareholder Yield % | 87.01 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -140.07 | |||||
| ROA % | -49.44 | |||||
| ROIC % | -138.4 | |||||
| 3-Year ROIIC % | -102.4 | |||||
| ROC (Joel Greenblatt) % | -162.41 | |||||
| ROCE % | -58.95 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.34 | |||||
| Price-to-Tangible-Book | 2.31 | |||||
| EV-to-EBIT | -0.6 | |||||
| EV-to-EBITDA | -0.62 | |||||
| EV-to-Forward-Revenue | 211.36 | |||||
| EV-to-FCF | -0.74 | |||||
| Earnings Yield (Greenblatt) % | -166.67 | |||||
| FCF Yield % | -137.44 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:UBX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Unity Biotechnology Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.53 | ||
| Beta | 1.72 | ||
| 3-Year Sharpe Ratio | -0.28 | ||
| 3-Year Sortino Ratio | -0.51 | ||
| Volatility % | 145.33 | ||
| 14-Day RSI | 27.94 | ||
| 14-Day ATR ($) | 0.169336 | ||
| 20-Day SMA ($) | 1.424605 | ||
| 12-1 Month Momentum % | 7.64 | ||
| 52-Week Range ($) | 0.88172 - 3.1 | ||
| Shares Outstanding (Mil) | 16.87 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Unity Biotechnology Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Unity Biotechnology Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Unity Biotechnology Inc Frequently Asked Questions
What is Unity Biotechnology Inc(UBX)'s stock price today?
The current price of UBX is $0.90. The 52 week high of UBX is $3.10 and 52 week low is $0.88.
When is next earnings date of Unity Biotechnology Inc(UBX)?
The next earnings date of Unity Biotechnology Inc(UBX) is 2025-05-14 Est..
Does Unity Biotechnology Inc(UBX) pay dividends? If so, how much?
Unity Biotechnology Inc(UBX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers